Hypofractionated Radiotherapy for Prostate Cancer

This trial aims to test a new radiation treatment for men with previously untreated high-risk prostate cancer. Researchers are evaluating the safety and effectiveness of two new radiation techniques used together, including hypofractionated radiotherapy with focal microboost. Participants will attend regular check-ups, complete questionnaires, and provide blood samples. Men with prostate cancer fitting a specific risk profile—such as high PSA levels or certain Gleason scores—might be suitable candidates. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group.

The trial does not specify if you need to stop taking your current medications, but you must stop using testosterone supplements before joining. It's best to discuss your specific medications with the trial team.

Previous studies have shown that hypofractionated radiotherapy with a focused microboost is quite safe for treating prostate cancer. Research indicates that patients did not experience severe side effects (grade 3 or higher) with this treatment, suggesting it is well-tolerated. The microboost technique targets extra radiation on specific areas and has been used safely, possibly improving treatment outcomes. Overall, both components of this treatment have been studied and appear to be safe options for prostate cancer patients.¹²³⁴⁵

Hypofractionated radiotherapy with a focal microboost is unique because it offers a new approach to treating prostate cancer by delivering higher doses of radiation in fewer sessions. Unlike the standard of care, which typically involves conventional fractionation over several weeks, this technique aims to complete treatment in a shorter timeframe, potentially reducing hospital visits and improving patient convenience. Researchers are excited about this treatment because it could enhance precision by targeting cancerous tissues more effectively while sparing healthy tissues, thereby minimizing side effects. This approach could lead to similar or even better outcomes compared to traditional methods, with a focus on improving patients' quality of life.

Research has shown that hypofractionated radiotherapy, which uses higher doses of radiation in fewer sessions, is as effective as traditional methods for treating prostate cancer. Studies have found that this approach helps prevent the cancer from worsening over time. Importantly, the treatment is generally safe, with no severe side effects reported in some studies. In this trial, participants will receive hypofractionated pelvic radiation with a focal microboost, which delivers extra radiation to specific areas. This technique aims to improve outcomes by targeting high-risk cancer spots. These findings suggest that combining both techniques could effectively treat high-risk prostate cancer.¹²³⁴⁶